• Tactivin (Thymus extract) 0.01% 1ml 5 vials

Expiration date: 05/2026

The composition and form of issue:

Solution for subcutaneous injection 1 amp. contains:

Tactivin 0.1 g

sodium chloride of 8.85 g

excipients: water for injection up to 1 l 

in 1 ml ampoules, complete with a knife ampulnam, in a cardboard bundle 5 or 10 ampoules.

Description pharmaceutical form:

Colorless transparent odorless liquid.

Feature:

The preparation of polypeptide nature in the form of solution for injection.

Description pharmacological action:

Is immunostimulating agent. With immunodeficiency the drug normalizes the quantitative and functional indices of immunity, stimulates the production of lymphokines, including &alpha - and &gamma - interferon restores the activity of T-killer cells, functional activity of hematopoietic stem cells and normalizes a number of other indicators of the intensity of immunity. Activates the macrophage system.

Indications:

Immunodeficiency States in adults and children (from 6 months to 14 years), resulting in such diseases as:

  • infectious purulent and septic processes
  • lymphoproliferative diseases (Hodgkin's disease, lymphocytic leukemia)
  • malignant neoplasms
  • persistent dysfunction of the thymus (radiation sickness, tumors of the thymus, surgical removal of the thymus)
  • multiple sclerosis
  • tuberculosis
  • recurrent eye herpes
  • psoriasis
  • shingles
  • dermatitis and dermatosis
  • frequently recurring viral respiratory infection
  • urological diseases of infectious etiology
  • lung disease
  • chronic viral hepatitis
  • surgery (in the preoperative and postoperative periods)
  • thymomegaly.

Contraindications:

  • pregnancy
  • the period of breastfeeding.

Side effects:

Allergic reactions.

Method of application and dose:

N/a, adult — 1 ml 0,01% solution (equivalent to 40 mg/m2 or 1-2 mg/kg) was administered the night, 1 time a day, daily for 5-14 days. If necessary, treatment is continued for 1 month 2 ml every 3rd day.

When persistent disorders of immunity Tactivin administered for 5-14 days at 2 ml daily and then 2 times a week for 2 ml within 6 months. Repeated courses of treatment prescribed for the indicators of immune status.

In multiple sclerosis the drug is administered daily 1 ml for 5 days, then — 2 ml 2 times a week for life.

In severe cases of multiple sclerosis Tactivin administered in complex therapy with corticosteroids (in the stage of application of corticosteroids 1 time per day). The reference drug is administered in the morning and Tactivin in the evening on 1 ml, in compliance with the interval between administration of corticosteroids and Tactivin 10-12 hours.

For the treatment of surgical patients Tactivin administered before surgery and 1 ml for 2 days and after it — within 5-14 days.

Malignancy Tactivin administered 5-6 day courses, 1 ml in between the courses of basic therapy.

For the treatment of recurrent ophthalmic herpes administered 0.1 ml of the drug under the conjunctiva, which is 4 mg/m2 or 0.1–0.2 ág/kg/day with an interval of 1 day for 4-5 days, either 1 ml s/C for 7-10 days.

If shingles inject 1 ml of Tactivin daily for 7-10 days.

The treatment can be repeated after 2-3 weeks.

In hepatitis of various etiologies Tactivin administered at 2-3 ml daily for 10-12 days in combination with basic drugs. The course of immune repeated after 7 days.

Children from 6 months to 14 years the drug is prescribed n/a the rate of 2-3 mg per 1 kg of body weight.

Frequent acute respiratory diseases, acute respiratory infections, septic infections, atopic dermatitis, complicated by the herpes virus, Tactivin administered daily for 7-10 days in combination with basic drugs. The subsequent introduction of the drug — 1 injection every other day for 1-2 weeks.

In malignant tumors and hepatitis in children treatment regimen does not differ from treatment regimens in adults.

It is recommended to enter in the evening between 17 and 20 hours.

Tactivin
(Thymus
extract)
0.01%
1ml
5
vials

  • $24.00